2,104
Participants
Start Date
June 1, 2020
Primary Completion Date
June 23, 2025
Study Completion Date
June 23, 2025
Roxadustat
Oral
Site JP00023, Aichi
Site JP00005, Akita
Site JP00002, Aomori
Site JP00012, Chiba
Site JP00038, Ehime
Site JP00018, Fukui
Site JP00040, Fukuoka
Site JP00007, Fukushima
Site JP00021, Gifu
Site JP00010, Gunma
Site JP00034, Hiroshima
Site JP00001, Hokkaido
Site JP00028, Hyōgo
Site JP00008, Ibaraki
Site JP00017, Ishikawa
Site JP00037, Kagawa
Site JP00046, Kagoshima
Site JP00014, Kanagawa
Site JP00039, Kochi
Site JP00043, Kumamoto
Site JP00026, Kyoto
Site JP00024, Mie
Site JP00004, Miyagi
Site JP00045, Miyazaki
Site JP00020, Nagano
Site JP00042, Nagasaki
Site JP00029, Nara
Site JP00015, Niigata
Site JP00003, Numakunai
Site JP00033, Okayama
Site JP00047, Okinawa
Site JP00027, Osaka
Site JP00044, Ōita
Site JP00041, Saga
Site JP00011, Saitama
Site JP00025, Shiga
Site JP00032, Shimane
Site JP00022, Shizuoka
Site JP00009, Tochigi
Site JP00036, Tokushima
Site JP00013, Tokyo
Site JP00031, Tottori
Site JP00016, Toyama
Site JP00030, Wakayama
Site JP00006, Yamagata
Site JP00035, Yamaguchi
Site JP00019, Yamanashi
Lead Sponsor
Astellas Pharma Inc
INDUSTRY